Of note, SRT is meanwhile feasible for up to 10 or even more brain lesions with excellent outcome [42,43], therefore use of the neurotoxic WBRT [44] should be strongly discouraged for ALK+ NSCLC, as long as potentially effective systemic treatments are still available. The gene discussed is ALK; the disease is non-small cell lung carcinoma.